Predictive medicine, personalized care
Proventys is developing a suite of software-based predictive and prognostic tests, delivered through Proventys PDx Oncology, to help clinicians assess certain patient risks and individualize treatment decisions. The first version of PDx Oncology includes the FN PDx™, a predictive test to assess a patient’s risk of febrile neutropenia, a serious complication of chemotherapy.
Under review by the FDA (de novo); not available for sale in the United States.